Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Myelofibrosis incidence is approximately 1-2 per 100,000 individuals per year, and median survival after diagnosis is six years

  60% confidence

• Menarini Group has a turnover of $5.5 billion, over 17,000 employees, 18 production sites, 9 R&D centers, and products available in 140 countries

  60% confidence

• SENTRY met its first co-primary endpoint: selinexor plus ruxolitinib achieved SVR35 of 49.8% vs 28.0% for ruxolitinib alone at week 24, a statistically significant improvement

  60% confidence

• Consistent SVR35 benefit was observed across prespecified subgroups, including patients receiving less than 15 mg of ruxolitinib per day

  60% confidence

• Variant allele frequency (VAF) reduction was observed in 32% of patients in the selinexor plus ruxolitinib arm vs 23.9% in the ruxolitinib alone arm at week 24, indicating potential for disease modification

  60% confidence

• The selinexor plus ruxolitinib combination demonstrated a manageable safety and tolerability profile consistent with known individual profiles of selinexor and ruxolitinib, with no new safety signals observed

  60% confidence

• The strength of the spleen response and encouraging early overall survival data from SENTRY creates hope for a potential new treatment option for myelofibrosis patients

  60% confidence

• SENTRY did not meet the second co-primary endpoint (Abs-TSS): combination arm showed 9.9 point improvement vs 10.9 point improvement for ruxolitinib alone at week 24, with no statistically significant difference between arms

  60% confidence

• Early overall survival data from SENTRY showed greater than 50% reduction in risk of death for patients receiving selinexor combination versus ruxolitinib alone, with hazard ratio of 0.43

  60% confidence

• Post-hoc analysis from Phase 3 SENTRY and new Phase 1 SENTRY data suggest SVR35 may predict overall survival

  60% confidence

• Spleen reduction is the essential goal of myelofibrosis treatment, and SENTRY's rapid, deep and durable results are associated with potential overall survival benefit and represent a potential new therapeutic advance

  60% confidence

Cited in these Via News reports

• FDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell Therapies →
• Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar →